Stem Cell

FDA publishes Celltex Therapeutics inspection 483

FDA publishes Celltex Therapeutics inspection 483

By Gareth Macdonald

The US FDA has published a 483 detailing the violations it observed during an inspection of stem cell firm Celltex Therapeutics in April and the document does not make for comfortable reading.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers